HUE068564T2 - Multispecifikus antitestek tisztítása - Google Patents

Multispecifikus antitestek tisztítása

Info

Publication number
HUE068564T2
HUE068564T2 HUE17751870A HUE17751870A HUE068564T2 HU E068564 T2 HUE068564 T2 HU E068564T2 HU E17751870 A HUE17751870 A HU E17751870A HU E17751870 A HUE17751870 A HU E17751870A HU E068564 T2 HUE068564 T2 HU E068564T2
Authority
HU
Hungary
Prior art keywords
purification
multispecific antibodies
multispecific
antibodies
Prior art date
Application number
HUE17751870A
Other languages
English (en)
Hungarian (hu)
Inventor
Glen Scott Giese
Eva Rosenberg
Bernard Sallier
Susanne Konrad
Wolfgang Koehnlein
Steffen Willmann
Agathe Bialas
Kimberly Ann Kaleas-Carroll
Yinges Yigzaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUE068564T2 publication Critical patent/HUE068564T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HUE17751870A 2016-06-17 2017-06-16 Multispecifikus antitestek tisztítása HUE068564T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351908P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
HUE068564T2 true HUE068564T2 (hu) 2025-01-28

Family

ID=59593150

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17751870A HUE068564T2 (hu) 2016-06-17 2017-06-16 Multispecifikus antitestek tisztítása

Country Status (18)

Country Link
US (1) US20190256556A1 (enExample)
EP (2) EP4549463A3 (enExample)
JP (3) JP2019521986A (enExample)
KR (3) KR102826635B1 (enExample)
CN (1) CN109563124A (enExample)
AR (1) AR108800A1 (enExample)
AU (2) AU2017286676B2 (enExample)
BR (1) BR112018075516A2 (enExample)
CA (1) CA3026518A1 (enExample)
ES (1) ES2988363T3 (enExample)
HR (1) HRP20241323T1 (enExample)
HU (1) HUE068564T2 (enExample)
IL (1) IL263690B2 (enExample)
MX (2) MX2018015173A (enExample)
PL (1) PL3472177T3 (enExample)
SG (1) SG11201810777WA (enExample)
TW (1) TWI798179B (enExample)
WO (1) WO2017218977A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2019043096A1 (en) * 2017-08-30 2019-03-07 Fresenius Kabi Deutschland Gmbh METHOD FOR PURIFYING IL-6 ANTI-RECEPTOR ANTIBODIES
US11945839B2 (en) 2017-12-22 2024-04-02 Hoffmann-La Roche Inc. Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019149691A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process
WO2019149693A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process and platform
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
KR20210121137A (ko) 2019-01-29 2021-10-07 샤이어-엔피에스 파마슈티칼즈, 인크. 부갑상선 호르몬 변이체
AU2020268896B2 (en) 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
CN114026108B (zh) * 2019-06-28 2024-09-10 夏尔巴生物技术(苏州)有限公司 无缝连续流层析方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2022554283A (ja) * 2019-11-07 2022-12-28 アムジエン・インコーポレーテツド 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分洗浄
WO2021099536A1 (en) * 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
AU2021208515A1 (en) * 2020-01-15 2022-08-04 F. Hoffmann-La Roche Ag Methods to decrease impurities from recombinant protein manufacturing processes
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2021170060A1 (en) * 2020-02-28 2021-09-02 Wuxi Biologics (Shanghai) Co., Ltd. Purification of bispeciifc antibodies
WO2021181417A1 (en) * 2020-03-11 2021-09-16 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
US20230143066A1 (en) * 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
AU2021265346A1 (en) * 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of affinity chromatography
CA3182314A1 (en) * 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2021220500A1 (ja) * 2020-05-01 2021-11-04 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 帯電物質の精製方法
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
WO2022061214A1 (en) * 2020-09-21 2022-03-24 Genentech, Inc. Purification of multispecific antibodies
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
SMT202500333T1 (it) 2020-12-18 2025-11-10 Richter Gedeon Nyrt Metodi per la purificazione di proteina di fusione fc-peptide
MX2023007028A (es) * 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
BR112023018268A2 (pt) * 2021-03-09 2023-10-31 Japan Chem Res Método para produzir uma proteína de fusão
US20240191179A1 (en) * 2021-04-23 2024-06-13 Kyowa Kirin Co., Ltd. Method for suppressing production of degradation products
CN117242095A (zh) * 2021-04-23 2023-12-15 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法
WO2022272119A2 (en) * 2021-06-25 2022-12-29 The Board Of Trustees Of The University Of Illinois Synthetic toolkit for plant transformation
EP4421089A4 (en) * 2021-10-19 2026-01-07 Alteogen Inc METHOD FOR PURIFYING A FUSION PROTEIN HAVING AN IGG FC DOMAIN
WO2024076990A1 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
CN117990807B (zh) * 2022-11-07 2024-09-24 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体电荷异质性的检测方法
CN119264256B (zh) * 2023-07-07 2026-01-02 齐鲁制药有限公司 一种单克隆抗体的纯化方法
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025029614A1 (en) * 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
WO2025088516A1 (en) * 2023-10-26 2025-05-01 Pfizer Inc. Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
WO2025155751A1 (en) * 2024-01-17 2025-07-24 Nutcracker Therapeutics, Inc. Improved method for isolating and characterizing proteins
CN122060072A (zh) * 2026-03-16 2026-05-19 齐鲁制药有限公司 一种法瑞西单抗的纯化方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541A (en) 1837-12-26 Daniel desmond
US7521A (en) 1850-07-22 Improvement in the
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1356052B1 (en) 2000-12-14 2008-08-20 Genentech, Inc. Production of full antibodies in procaryotic cells
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
WO2012059495A1 (en) * 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2578286A1 (en) * 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
SI3495387T1 (sl) * 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
KR102250937B1 (ko) * 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
CN118271429A (zh) * 2013-08-19 2024-07-02 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
WO2015061526A1 (en) * 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
US20160272673A1 (en) * 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
EP3116891B1 (en) * 2014-03-10 2020-02-12 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions

Also Published As

Publication number Publication date
CN109563124A (zh) 2019-04-02
JP2019521986A (ja) 2019-08-08
BR112018075516A2 (pt) 2019-10-01
WO2017218977A3 (en) 2018-01-18
AU2024227572A1 (en) 2024-11-14
AU2017286676A8 (en) 2018-12-20
IL263690A (en) 2019-01-31
IL263690B1 (en) 2023-01-01
SG11201810777WA (en) 2018-12-28
MX2024003651A (es) 2024-04-15
IL263690B2 (en) 2023-05-01
KR20190039929A (ko) 2019-04-16
MX2018015173A (es) 2019-07-04
KR20250107275A (ko) 2025-07-11
JP2022166004A (ja) 2022-11-01
WO2017218977A2 (en) 2017-12-21
JP2024156655A (ja) 2024-11-06
EP3472177B1 (en) 2024-08-14
AU2017286676A1 (en) 2018-12-13
CA3026518A1 (en) 2017-12-21
TW201803902A (zh) 2018-02-01
WO2017218977A8 (en) 2019-03-28
JP7564843B2 (ja) 2024-10-09
TWI798179B (zh) 2023-04-11
ES2988363T3 (es) 2024-11-20
HRP20241323T1 (hr) 2024-12-20
KR102826635B1 (ko) 2025-06-30
PL3472177T3 (pl) 2024-11-25
AU2017286676B2 (en) 2024-07-25
AR108800A1 (es) 2018-09-26
KR20230113662A (ko) 2023-07-31
EP3472177A2 (en) 2019-04-24
EP4549463A2 (en) 2025-05-07
JP7881651B2 (ja) 2026-06-29
US20190256556A1 (en) 2019-08-22
EP4549463A3 (en) 2025-07-30
EP3472177C0 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
PL3472177T3 (pl) Oczyszczanie przeciwciał wieloswoistych
IL285366A (en) Multispecific antigen-binding proteins
PT3268390T (pt) Métodos de purificação de anticorpos biespecíficos
ZA201605660B (en) Multispecific antibodies
PL3227332T3 (pl) Wielospecyficzne przeciwciała
HUE059158T2 (hu) Eljárás pridopidin elõállítására
GB201414823D0 (en) Multispecific antibodies
ZA201700880B (en) Polymorphs of selinexor
PL3458100T3 (pl) Selektywna redukcja przeciwciał ze zmodyfikowaną cysteiną
GB201516516D0 (en) Process of manufacture
IL248697A0 (en) Methods for purifying antibodies
GB201521581D0 (en) Methods of purifying nanostructures
ZA201808524B (en) Methods of affecting separation
ZA201903408B (en) Process for purification of pyrazolpyridazines
SG10202007893TA (en) Methods of immunotherapy
SG11201607098SA (en) Antibody purification process
SG11201710689TA (en) Process of purifying methionine
SG11201608513WA (en) Novel purification process of gonadotropin
GB201609314D0 (en) Methods of forming compounds
GB201512678D0 (en) Methods of chemical synthesis
SG11201802755WA (en) Process for purification of methyl methacrylate
ZA201608307B (en) Process for the purification of l-alpha-glycerophosphorylcholine
PT3247481T (pt) Purificação de plastificantes
GB201700973D0 (en) Process of manufacture
ZA201902183B (en) Purification process of fviii